1. Home
  2. EXAI vs AACT Comparison

EXAI vs AACT Comparison

Compare EXAI & AACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAI
  • AACT
  • Stock Information
  • Founded
  • EXAI 2012
  • AACT 2021
  • Country
  • EXAI United Kingdom
  • AACT United States
  • Employees
  • EXAI N/A
  • AACT N/A
  • Industry
  • EXAI Biotechnology: Biological Products (No Diagnostic Substances)
  • AACT
  • Sector
  • EXAI Health Care
  • AACT
  • Exchange
  • EXAI Nasdaq
  • AACT Nasdaq
  • Market Cap
  • EXAI 613.6M
  • AACT 677.5M
  • IPO Year
  • EXAI 2021
  • AACT 2023
  • Fundamental
  • Price
  • EXAI $4.84
  • AACT $10.91
  • Analyst Decision
  • EXAI Hold
  • AACT
  • Analyst Count
  • EXAI 4
  • AACT 0
  • Target Price
  • EXAI $7.00
  • AACT N/A
  • AVG Volume (30 Days)
  • EXAI 828.8K
  • AACT 240.5K
  • Earning Date
  • EXAI 11-08-2024
  • AACT 01-01-0001
  • Dividend Yield
  • EXAI N/A
  • AACT N/A
  • EPS Growth
  • EXAI N/A
  • AACT 48.19
  • EPS
  • EXAI N/A
  • AACT 0.43
  • Revenue
  • EXAI $22,877,630.00
  • AACT N/A
  • Revenue This Year
  • EXAI $156.33
  • AACT N/A
  • Revenue Next Year
  • EXAI N/A
  • AACT N/A
  • P/E Ratio
  • EXAI N/A
  • AACT $25.33
  • Revenue Growth
  • EXAI N/A
  • AACT N/A
  • 52 Week Low
  • EXAI $3.80
  • AACT $10.35
  • 52 Week High
  • EXAI $7.91
  • AACT $11.00
  • Technical
  • Relative Strength Index (RSI)
  • EXAI 44.03
  • AACT 60.62
  • Support Level
  • EXAI $4.45
  • AACT $10.89
  • Resistance Level
  • EXAI $4.85
  • AACT $10.95
  • Average True Range (ATR)
  • EXAI 0.38
  • AACT 0.02
  • MACD
  • EXAI -0.07
  • AACT 0.00
  • Stochastic Oscillator
  • EXAI 19.12
  • AACT 57.89

About EXAI Exscientia Plc

Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.

About AACT Ares Acquisition Corporation II

Ares Acquisition Corp II is a blank check company.

Share on Social Networks: